title: Functional characterization of receptors with affinity for PYY, NPY, [Leu31,Pro34]NPY and PP in a human colonic epithelial cell line.
abstract: 1. Confluent epithelial layers of a human adenocarcinoma cell line called Colony-6 have been shown to respond to nanomolar concentrations of vasoactive intestinal polypeptide (VIP), peptide YY (PYY), neuropeptide Y (NPY) and somatostatin (Som). 2. The VIP-induced increase in basal short-circuit current (SCC) was attenuated by basolateral application of Som, PYY or NPY, and also by the Y1-receptor agonist [Leu31,Pro34]NPY, as well as pancreatic polypeptide (PP). High concentrations (0.1-3.0 microM) of NPY(2-36) were effective but the C-terminal fragment NPY(13-36) (0.1-1.0 microM) and desamidoNPY (0.6 microM) were not active. A rank order of agonist EC50 values was: PYY > NPY > [Leu31,Pro34]NPY > PP > NPY(2-36) >> NPY (13-36). 3. Receptors for all these peptides were preferentially located within the basolateral domain. Apical addition of PP (1 microM) and Som (100 nM) had no effect upon basal SCC while apical VIP (10 nM) responses were 18%, and apical PYY (100 nM) were 27% the size of respective basolateral controls (100%). 4. Cross-desensitization was observed between [Leu31,Pro34]NPY (1 microM) and both PYY (100 nM) and PP (1 microM) and between PYY and NPY(2-36) (1 microM), but was not significant between PYY (100 nM) and PP (1 microM). We suggest that either these cells express a single new Y-receptor with an unusual phenotype or that two Y-receptor populations exist in Colony-6 cells.
authors.affiliation: Epithelial Research Unit, Royal College of Surgeons of England, London.
authors.forename: H M
authors.initials: HM
authors.lastname: Cox
authors.forename: I R
authors.initials: IR
authors.lastname: Tough
mesh_terms: D000230:Adenocarcinoma; D003106:Colon / Q000378:metabolism* / Q000648:ultrastructure*; D003110:Colonic Neoplasms; D004848:Epithelium / Q000378:metabolism / Q000648:ultrastructure; D006801:Humans; D009478:Neuropeptide Y / Q000031:analogs & derivatives* / Q000378:metabolism*; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D019894:Peptide YY; D010455:Peptides / Q000378:metabolism*; D011964:Receptors, Gastrointestinal Hormone / Q000378:metabolism*; D017476:Receptors, Neuropeptide Y / Q000378:metabolism; D012636:Secretory Rate / Q000187:drug effects; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D009478:Neuropeptide Y; D010455:Peptides; D011964:Receptors, Gastrointestinal Hormone; D017476:Receptors, Neuropeptide Y; C082172:peptide YY receptor; C029438:receptors, pancreatic polypeptide-specific; D019894:Peptide YY; C062259:neuropeptide Y, Leu(31)-Pro(34)-; D014660:Vasoactive Intestinal Peptide; D010191:Pancreatic Polypeptide